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In this study, we explore the therapeutic potential of lapatinib a selective inhibitor of both the EGFR and HER2 tyrosine kinases for
the treatment of endometrial cancer. The effect of lapatinib on tumour cell growth and receptor activation was studied in a panel of
human endometrial cancer cell lines. Candidate molecular markers predicting sensitivity were assessed by baseline gene expression
profiling, ELISA, and western blot analyses. Multiple drug effect/combination index (CI) isobologram analysis was used to study the
interactions between chemotherapeutic drugs and lapatinib. Concentration-dependent anti-proliferative effects of lapatinib were
seen in all endometrial cancer cell lines tested, but varied significantly between individual cell lines (IC50 range: 0.052–10.9mmol).
HER2 overexpression or increased expression of EGFR was significantly associated with in vitro sensitivity (P¼0.024 or 0.011,
respectively). Lapatinib exerts growth inhibition in a PTEN-independent manner. Sensitive cell lines also exhibited increased
expression of EGFR ligands or HER3. In contrast, lapatinib-resistant cell lines exhibited high androgen receptor (AR) levels or
epithelial-to-mesenchymal transition (post-EMT) features. In endometrial cancer cells, at a wide range of clinically achievable drug
concentrations, additive and synergistic interactions were observed for lapatinib plus carboplatin, paclitaxel, docetaxel, and
doxorubicin. These observations provide a clear biologic rational to test lapatinib as a single agent or in combination with
chemotherapy in endometrial cancer with HER2 overexpression. Expression of EGFR, its ligands, HER3, AR, and post-EMT markers
warrant further evaluation to help define patients with HER2-nonoverexpressing endometrial cancer most likely to benefit from
lapatinib.
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Endometrial cancer is the most common malignancy of the female
reproductive tract. Despite recent advances in the molecular
characterisation of endometrial cancer, current treatment strate-
gies do not include target-based therapies (Murphy, 1994; Mariani
et al, 2005). Among the peptide growth factor receptors frequently
implicated in endometrial cancer are members of the type I
receptor tyrosine kinase family, which includes HER1 (epidermal
growth factor receptor (EGFR)), HER2, HER3, and HER4
(Srinivasan et al, 1999; Santin et al, 2002). Amplification of the
HER2 gene, resulting in overexpression of the receptor, is more
commonly found in nonendometrioid endometrial cancers (type II
endometrial cancers) and is associated with an aggressive form of
the disease with significantly shortened disease-free survival and
overall survival (Hetzel et al, 1992; Acharya et al, 2005). Recent
studies including patients with endometrial cancer of diverse
histologic type demonstrated HER2 gene amplification in 17/58
(29%) or 11/26 (42%) of uterine serous papillary cancers and 8/63
(13%) grade 3 endometrioid endometrial cancers (Santin et al,
2005; Morrison et al, 2006).
Epidermal growth factor receptor expression has been demon-
strated in 43–67% of patients with endometrial cancer and has
similarly been associated with significantly shortened disease-free
and overall survival (Khalifa et al, 1994; Scambia et al, 1994;
Niikura et al, 1995). Moreover, endometrial cancer demonstrated
significantly higher expression levels of the EGFR ligands TGF-a
and amphiregulin compared with normal endometrium (Pfeiffer
et al, 1997; Ejskjaer et al, 2007). The central role of HER2 and
EGFR in growth and differentiation of both normal and malignant
cancer cells and their availability to extracellular manipulation
make both HER2 and EGFR attractive targets for pharmacological
intervention. Recently, agents have been developed that simulta-
neously inhibit both the EGFR and HER2 epithelial growth factor
receptors (Rusnak et al, 2001a). Lapatinib is such a synthetic small
molecule inhibitor of the HER2 and EGFR tyrosine kinases
(Rusnak et al, 2001b). Inhibiting both receptors may be
particularly attractive as interactions between HER2 and EGFR
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(Konecny et al, 2006).
Our primary aim was to explore the in vitro effects of this dual
receptor tyrosine kinase inhibitor (TKI) in an unbiased way using
a large panel of 19 endometrial cancer lines that express variable
levels of HER2 and EGFR. Subsequently, all cell lines were
molecularly characterised using Agilent Microarrays. Although
this technology allows us to examine thousands of genes
simultaneously the identification of a more limited number of
markers that predict response to lapatinib in endometrial cancer
cells might be more useful for independent validation in clinical
studies. Importantly, for this study markers were selected on the
basis of their potential biologic relevance in HER2 and EGFR
signalling. Therefore, we correlated the IC50 values with the relative
expression levels of EGFR, HER2, HER3, and HER4 as well as the
ligands of EGFR such as TGF-a, EGF, amphiregulin, HB-EGF,
betacellulin, epiregulin, neuregulin 1, and neuregulin 2. Next, we
correlated the relative expression of the steroid hormone receptors
oestrogen receptor-a (ER-a)o r- b (ER-b), progesterone receptor
(PR), and androgen receptor (AR) with in vitro response to
lapatinib, because recent studies suggest that EGFR inhibitors may
be particularly active in a subset of breast tumours described as
‘triple negative’ (ie, negative ER, PR, and HER2 expression) (Finn
et al, 2006). Furthermore, the identification of novel therapies in
particularly aggressive tumour cells that have undergone a shift
from epithelial differentiation towards a mesenchymal phenotype
is a clinical priority. This process referred to as epithelial-to-
mesenchymal transition (EMT), increases motility and invasive-
ness of tumour cells and is often considered a prerequisite for
tumour infiltration and metastasis (Thiery and Sleeman, 2006). To
further determine the potential clinical role of lapatinib in
particularly aggressive endometrial cancer cells we compared the
in vitro effects of lapatinib between both of these subtypes.
Finally, we used multiple drug effect/combination index (CI)
isobologram analysis to study the efficacy of chemotherapeutic
drugs plus lapatinib combinations tested against lapatinib-
sensitive HER2-amplified/overexpressing or EGFR-expressing en-
dometrial cancer cells.
In summary, the current studies were intended to provide a
rational to test lapatinib as a single agent or in combination with
chemotherapy in patients with high-risk primary or metastatic
endometrial cancer and to identify candidate markers that may
help define subsets of patients most likely to benefit from
treatment with lapatinib.
MATERIALS AND METHODS
Cell lines, cell culture, and reagents
The effects of lapatinib on malignant cell growth were studied in a
panel of 19 established human endometrial cancer cell lines. The
established human endometrial carcinoma cell lines KLE, RL-95-2,
AN3CA, HEC1A, and HEC1B were obtained from American Type
Culture Collection (Rockville, MD, USA). The established human
endometrial cancer cell lines MFE280, MFE296, MFE319, EFE184,
and EN were obtained from the German Tissue Repository DSMZ
(Braunschweig, Germany). Ishikawa cells were obtained from the
European Collection of Cell Cultures (ECACC, Salibury, Wiltshire,
England). The established human endometrial carcinoma cell lines
HEC155, SNG-II, and SNG-M were obtained from the Japanese
Health Science Research Resources Bank (Osaka, Japan). The cell
lines SPAC1S and SPAC1L were provided by the laboratory of Dr Y
Hirai from the Department of Gynecology, Cancer Institute
Hospital (Tokyo, Japan). The cell line EN1 was provided by Dr
VM o ¨bus from Department of Gynecology at the University of Ulm
(Germany). USPC1 and USPC2 cells were provided by Dr A Santin
from the Department of Obstetrics and Gynecology, Division of
Gynecologic Oncology at the University of Arkansas (Little Rock,
AR, USA). USPC2, RL-95-2, SPAC1L, SPAC1S, and HEC1B cells
were cultured in RPMI medium 1640 supplemented with 10% heat-
inactivated fetal bovine serum, 2mM glutamine, and PSF (Irvine
Scientific, Santa Ana, CA, USA). HEC1A cells were cultured in
McCoy’s medium supplemented with 10% heat-inactivated fetal
bovine serum and PSF (Irvine Scientific). SNG-II and SNG-M cells
were cultured in Ham’s F-12 supplemented with 10% heat-
inactivated fetal bovine serum and PSF (Irvine Scientific). The
remaining cell lines were cultured in DMEM medium supplemen-
ted with 10% heat-inactivated fetal bovine serum, 2mM glutamine,
and PSF (Irvine Scientific). Lapatinib was provided by Glaxo-
SmithKline (Research Triangle Park, NC, USA) as a 10-mM
concentrated stock solution in dimethyl sulphoxide.
Quantitation of HER2 and EGFR expression
HER2 and EGFR protein content in all cell lines was measured by
ELISA as described previously (Konecny et al, 2006) (HER2 ELISA;
Oncogene Research Products, Calbiochem, San Diego, CA, USA
and EGFR ELISA; R&D Systems, Minneapolis, MN, USA).
Proliferation assays
Cells were plated into 24-well plates at a density of 2 to 5 10
5 and
grown in cell line-specific media without or with increasing
concentrations of lapatinib (ranging between 0.031 and 10mM).
Cells were harvested by trypsinisation on day 7 and counted using
a particle counter (Z1; Beckman Coulter Inc., Fullerton, CA, USA).
Growth inhibition was calculated as a percentage of the untreated
controls. Experiments were performed three times in duplicate for
each cell line. The log of the fractional growth inhibition was then
plotted against the log of the drug concentration, and the IC50
values were interpolated from the resulting linear regression curve
fit (CalcuSyn; Biosoft, Ferguson, MO, USA).
Western blots and immunoprecipitation
Cells in log-phase growth were washed in PBS and lysed at 41Ci n
lysis buffer. Insoluble material was cleared by centrifugation at
10000g for 10min. Protein was quantitated using BCA (Pierce
Biochemicals, Rockford, IL, USA), resolved by SDS-PAGE, and
transferred to nitrocellulose membranes (Invitrogen, Carlsbad,
CA, USA). HER2, EGFR, and PTEN expression were detected,
respectively, by monoclonal anti-HER2 (Ab-3; Calbiochem), anti-
EGFR antibodies (Pharmingen; San Diego, CA, USA), and anti-
PTEN antibodies (PTEN 7974; Santa Cruz Biotechnology, Santa
Cruz, CA, USA). For the evaluation of concentration-dependent
activity of lapatinib on HER2, EGFR, AKT, and ERK Phosphoryla-
tion, USPC1, USPC2, RL-95-2, HEC155, and SNG-II cells in log-
phase growth were treated with increasing doses of lapatinib
(0.5–5mM) for 1h prior to cell lysis. Tyrosine phosphorylation of
HER2 and EGFR was analysed as follows. Immunoprecipitations
were performed by allowing 250mg protein lysate to incubate with
3mg monoclonal anti-HER2 (Ab-3) or anti-EGFR antibody (Ab-1;
Calbiochem), and Protein A/G-agarose (Santa Cruz Biotechnology)
at 41C overnight with gentle agitation. The immunoprecipitates
were washed three times in lysis buffer and then denatured in
Lemmli’s buffer prior to SDS-PAGE. Immunoblotting was
performed using a monoclonal anti-phosphotyrosine antibody
(Upstate, Charlottsville, VA, USA). Detection was performed using
ECL Plus chemifluorescent reagent (Amersham Biosciences,
Piscataway, NJ, USA) and imaging of the resulting western blots
was performed using the chemifluorescence method by Typhoon
9400 (Amersham Biosciences). Phospho-AKT and phospho-ERK
were detected by polyclonal anti-pAKT (Ser473) and anti-pERK
(Thr202/Thr204) antibodies (Cell Signaling, Beverly, MA, USA).
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HER2 gene copy number was analysed using fluorescence in situ
hybridisation (FISH). In 12 established endometrial cancer cell
lines (EN, Ishikawa, KLE, RL-95-2, HEC155, HEC1A, HEC1B,
MFE319, MFE280, MFE296, USPC1, and USPC2). The cell lines
were treated with Colcemid (0.05gml
 1) for 2–4h to obtain
metaphase preparations. All samples were fixed in methanol/acetic
acid (3:1). Specimen preparation, hybridisation, and microscopy
were performed as previously described (Pauletti et al, 2000). A
multicolor topo-II-alpha spectrum orange, HER2 spectrum green,
and CEP17 spectrum aqua probe was used (Vysis Inc., Downers
Grove, IL, USA). Data were expressed in terms of HER2/neu and
topo-II-alpha genes per chr.17cen., with two HER2 or topo-II-
alpha genes per chr.17cen. as the biologic cutoff point to
distinguish cell lines with or without HER2 and topo-II-alpha
amplification.
Multiple drug effect analysis
Aliquots of 3 to 5 10
3 USPC1, USPC2, RL-95-2, and HEC155 cells
were plated in 96-well microdilution plates. Following cell
adherence (24h), experimental media containing either control
media, lapatinib, chemotherapeutic agent, or the combination
(lapatinib plus chemotherapeutic agent) were added to appropriate
wells in duplicate, and serial two-fold dilutions were performed to
span clinically relevant concentration ranges for the dose–effect
analysis for lapatinib and drug combinations. Following incuba-
tion for 72–120h, plates were washed with PBS and stained with
0.5% N-hexamethylpararosaniline (crystal violet) in methanol.
Sorenson’s buffer (0.025 M sodium citrate, 0.025 M citric acid in
50% ethanol) (0.1ml) was added to each well, and the plates were
analysed in an ELISA plate reader at 540nm wavelength. For each
assay, the log of the fractional growth inhibition was plotted
against the log of the drug concentration and the linear regression
curve fit correlation coefficient (r-value) was calculated. Multiple
drug effect analysis was performed using computer software
(Biosoft) as described in detail (Pegram et al, 2004). In this
analysis, synergy is defined as CI values significantly lower than
1.0, antagonism as CI values significantly higher than 1.0, and
additivity as CI values equal to 1.0.
Microarray analysis
Agilent microarray analyses were developed for each cell line.
Briefly, cells were grown to log phase, and then RNA was extracted
using the RNeasy Kit (Qiagen, Valencia, CA, USA). The purified
RNA was eluted in 30–60ml DEPC water and the quantity of RNA
measured by spectral analysis using the Nanodrop Spectro-
photometer. RNA quality was determined by separation of the
RNA via capillary electrophoresis using the Agilent 2000
Bioanalyzer. Microarrays of endometrial cancer cell lines were
then performed on the Agilent Human 1A V1 chip. Characterisa-
tion of individual breast cancer cell lines by comparison to an
endometrial cancer cell line mixed reference pool was conducted
on a single slide in which the mixed pool RNA was labelled with
cyanine-3 and the individual cell lines with cyanine-5. The mixed
reference pool consisted of equal amounts of cRNA from
endometrial cancer cell lines that were selected to be representative
of a range of the various known endometrial cancer subtypes. The
reference includes 18 cell lines (all mentioned above except
USPC1). Microarray slides were read using an Agilent Scanner, and
the Agilent Feature Extraction software version 7.5 was used to
calculate gene expression values. Extracted data were imported
into Rosetta Resolver 5.1 to create expression profiles for each
individual endometrial cell line experiment. Cluster analysis was
performed in Resolver and cell line profiles were exported to Excel
(Microsoft, Redmond, WA, USA) for additional analysis.
Statistical methods
Associations between the expression levels of biomarkers and the
IC50 values were analysed using Spearman’s r correlation, and
differences in the IC50 values between subgroups compared using
the Mann–Whitney U-test. All statistical tests were two sided. The
threshold for upregulation was set to log (ratio) 40.13 with a
P-value o0.01, and downregulation was defined as log (ratio) p0.13
with a P-value o0.01. The P-values were determined according to
the Agilent error model when the feature-extracted data were
imported into Resolver. This study was reviewed and approved by
the Mayo Clinic Foundation Institutional Review Board.
RESULTS
Activity of lapatinib in human endometrial cancer cells
The effects of lapatinib on human endometrial cancer cells were
evaluated using a panel of 19 established endometrial cancer cell
lines that expresses widely varying levels of EGFR and HER2
(Table 1). These cell lines were selected to be representative of a
range of endometrial cancer subtypes. Five cell lines (USPC1,
USPC2, HEC155, SPAC1L, and SPAC1S) were obtained from
patients with type II uterine serous papillary endometrial cancer
(Hirai et al, 1994; Santin et al, 2002; Iida et al, 2004). The
remaining cell lines are derived from type I endometrioid
endometrial cancers. An exception is the cell line MFE319, which
originates from an endometrial adenosquamous carcinoma
(Hackenberg et al, 1997). To determine the relative effect of
expression levels of HER2 and EGFR on lapatinib response, the
EGFR and HER2 receptor content of the various cell lines used in
the in vitro studies was quantitated using ELISA (Table 1). The
receptor expression was further confirmed by western blot analysis
(data not shown). Two out of the 19 established endometrial
cancer cell lines (USPC1 and USPC2) demonstrated high levels
of HER2 expression similar to the levels seen in the HER2-
overexpressing breast cancer cell line SK-BR-3 known to have
amplification of the HER2 gene. The HER2 protein levels in these
HER2-overexpressing endometrial cancer cell lines ranged between
288ng per mg protein (USPC1) and 1377ng per mg protein
Table 1 Lapatinib concentrations that achieve 50% growth inhibition
(IC50), and the corresponding levels of HER2 and EGFR expression as
measured by ELISA
Cell line
IC50
(lmol) SE
HER2
(ngmg
 1)S E
EGFR
(ngmg
 1)S E
USPC2 0.052 0.370 1377 39 66 9.0
USPC1 0.607 0.245 288 16 38 1.0
EFE184 0.649 0.436 1.9 0.5 9.0 0.4
HEC155 0.790 0.052 5.0 0.1 98 1.7
RL-95-1 0.927 0.077 3.5 1.0 228 18
SNG-II 1.534 0.153 8.1 0.6 208 6.8
MFE319 1.597 0.267 7.7 1.0 22 1
SPAC1S 1.652 0.274 10 1.3 24 4.0
SNG-M 3.26 0.529 13 0.3 103 3.4
KLE 3.298 0.420 17 3.0 23 4.0
MFE280 3.566 0.207 3.6 1 1.2 0.3
EN1 3.756 0.367 22 4 29 1.3
HEC1A 4.011 0.872 4.1 1 36 1.3
EN 5.334 0.450 14 0.9 2.7 0.9
AN3CA 6.099 1.187 3.0 1 12 1.3
HEC1B 6.368 0.424 8.8 1 9.4 1.2
SPAC1L 7.102 0.302 6.9 0.5 18 3.8
Ishikawa 8.137 0.503 14 1.5 15 3.3
MFE296 10.973 0.723 2.93 1.0 2.85 1.0
EGFR¼epidermal growth factor receptor.
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HER2 gene amplification with USPC1 demonstrating an average of
10 signals per cell and USPC2 showing the presence of signal
cluster(s) of more than 25 scattered signals per cell. Precise signal
enumeration of high-level amplification was not possible because
of coalescing fluorescence of signal cluster(s) (Figure 1B). Neither
of the two HER2-amplified cell lines demonstrated coamplification
of the topo-II-alpha gene (Figure 1B). Four of the established
endometrial cancer cell lines (HEC155, SNG-II, SNG-M, and RL-
95-2) expressed EGFR at high levels comparable to those seen in
breast cancer cells known to express high level of EGFR (Konecny
et al, 2006). The EGFR protein expression in these cell lines ranged
between 98ng per mg protein (HEC155) and 228ng per mg protein
(RL-95-2). All of the remaining established human endometrial
cancer cell lines expressed varying but lower levels of EGFR
compared with the HEC155, SNG-II, SNG-M, or RL-95-2 cells
(Table 1).
After quantitation of EGFR and HER2 receptor levels in the
endometrial cancer cell lines, growth assays were performed
(Table 1 and Figure 1A). The effective dose range for each drug
(IC10–IC80) was identified using a wide range of lapatinib
concentrations (0.031–10mM). Lapatinib inhibited the prolifera-
tion of all endometrial cancer cell lines investigated in a
concentration-dependent fashion; however, the IC50 values varied
significantly between individual cell lines with up to a 200-fold
difference in the IC50 values and ranged between 0.052mM in
HER2-overexpressing USPC2 endometrial cancer cells and 10.9mM
in MFE296 cells that express low levels of HER2 and EGFR
(Table 1). Both HER2-overexpressing endometrial cancer cell lines
had significantly lower IC50 values compared with nonoverexpres-
sing cell lines (Figure 1C; mean IC50 value 0.33 vs 4.15; P¼0.024),
and EGFR expression was significantly inversely correlated with
IC50 values (Figure 1C; Spearman r, r¼ 0.57, P¼0.011). We next
investigated the sensitivity of the endometrial cancer cell lines to
lapatinib by using a binary classification, and thus two classes of
cell lines were defined: sensitive and resistant. Using the median
IC50 value as a cutoff cell lines with an IC50 below 3mmol were
classified as sensitive and those with higher IC50 values as
resistant. Using this binary classification, 4/5 uterine serous
papillary cell lines and all 6 cell lines with either high HER2
(USPC1 and USPC2) or EGFR (HEC155, RL-95-2, SNG-II, and
SNG-M) expression were classified as sensitive. In contrast, none
of the resistant cell lines demonstrated HER2 overexpression or
high levels of EGFR expression. Among those cell lines with low
levels of HER2 and EGFR expression, only EFE184 demonstrated
responsiveness to lapatinib at nanomolar concentrations (IC50
0.649mM).
Effects of lapatinib on HER2, EGFR, AKT, and ERK
signalling in endometrial cancer cells
As a measure of functional activity of the receptor tyrosine kinases,
the phosphorylation state of HER2 or EGFR was assessed using
immunoblotting techniques. Exposure of USPC1, USPC2, RL-95-2,
HEC155, and SNG-II human endometrial cancer cells to lapatinib
resulted in a dose-dependent reduction of phosphorylation of both
the EGFR and HER2 receptor tyrosine kinases and their down-
stream signalling intermediates AKT and ERK (Figure 2A). Of
note, lapatinib was not able to inhibit AKT phosphorylation in
both RL-95-2 and SNG-II cells. RL-95-2 cells are known to be
PTEN mutated (Gagnon et al, 2003). Inactivation of PTEN leads to
activation of downstream PI3K with subsequent activation of the
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Figure 1 (A) Growth inhibitory effects of lapatinib were studied across a panel of endometrial cancer cell lines. Cells were grown in cell line-specific
media without or with increasing doses of lapatinib (ranging between 0.031 and 10mM). Cells were trypsinised and counted after 7 days of treatment. The
percentage of inhibition was calculated compared with untreated controls. The log of the fractional growth inhibition was plotted against the log of the drug
concentration. The dose achieving 50% growth inhibition (IC50) was interpolated from the resulting linear regression curve fit. Cell lines are ordered from left
to right from low to high IC50 values. Error bars indicate the SE of the mean value. Mean is derived from three replicate experiments. (B) HER2 and topo-II-a
gene copy number were analysed by FISH using a multicolor topo-II-alpha spectrum orange, HER2 spectrum green, and CEP17 spectrum aqua probe (Vysis
Inc.). (C) Epidermal growth factor receptor and HER2 expression were assessed by ELISA for each of the endometrial cancer cell lines. Epidermal growth
factor receptor was correlated with the corresponding IC50 value (Spearman’s r correlation coefficient). For HER2, the IC50 values were compared between
cell lines with HER2 overexpression and those without using the Mann–Whitney test for statistical comparison.
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PTEN with failure to inhibit AKT leads to in vitro resistance
towards EGFR TKIs (She et al, 2003). In our studies, however, both
RL-95-2 and SNG-II were among the most sensitive cell lines
despite lack of AKT inhibition through lapatinib. To better
understand the association between PTEN deficiency and response
to TKIs, we assessed PTEN expression in all of the 19 endometrial
cancer cell lines using western blot analysis and compared the in
vitro sensitivity towards lapatinib between lines with low and those
with high expression levels (Figure 2B). Low expression of PTEN
(as seen in SNG-II, Ishikawa, MFE319, EN1, RL-95-2, EN, AN3CA,
SPAC1S, SNG-M, and SPAC1L cells) was not associated with
resistance towards lapatinib when compared with those cell lines
with high levels of PTEN expression (mean IC50 4.09 vs 3.37,
P¼0.617).
Novel predictive markers
A key aspect of therapies with targeted agents is accurate selection
of patients most likely to benefit from therapy. Our preclinical data
demonstrate that increased expression of either HER2 or EGFR
was significantly associated with in vitro sensitivity to lapatinib
(Table 1; Figure 1C). Moreover, we were able to demonstrate a
significant inverse correlation between IC50 values and the relative
expression of the autocrine EGFR ligand amphiregulin (r¼ 0.56,
P¼0.012), and HER3, the preferred oligomerisation partner of
HER2 (r¼ 0.56, P¼0.012), suggesting that lapatinib-sensitive
cell lines have higher levels of amphiregulin or HER3 expression
(Table 2; Figure 3A). Other EGFR ligands such as neuregulin 1,
TGF-a, and epiregulin showed a similar inverse correlation with
the IC50 values, although not at a statistically significant level
(Table 2). We found no association between low ER-a, ER-b,o rP R
expression and improved in vitro response; however, lapatinib-
sensitive cell lines did have lower levels of AR expression (r¼0.52,
P¼0.021).
Induction of regulators of an EMT, such as Twist, Slug, and
Snail, represses epithelial cadherin transcription in cancer cells,
causing downregulation of this adhesive epithelial marker (Cowin
et al, 2005). Conversely, mesenchymal markers, such as vimentin
(VIM), are induced in these cancer cells, all leading to a less
adhesive, more motile cell morphology that allows local tumour
cell evasion (Cowin et al, 2005). A cluster diagram of the 19
endometrial cancer cell lines was developed using the markers
VIM, E-cadherin (CDH1), P-cadherin (CDH3), and the cytoker-
atins (KRT) 5, 6, 8, 18, and 19 (Figure 3B). Several endometrial
cancer cell lines were classified as representing endometrial cancer
cells that have undergone an EMT (post-EMT). Post-EMT cell lines
with high expression of VIM, and low expression of CDH1 or
CDH3 also demonstrated lower expression levels of epithelial KRT
pY-HER2
pY-EGFR
p-AKT
p-ERK 
Lapatinib (M)
0 0.5 2 5
USPC1 USPC2 RL-95-2
Lapatinib (M)
0 0.5 2 5
Lapatinib (M)
0 0.5 2 5
Lapatinib (M)
0 0.5 2 5
Lapatinib (M)
0 0.5 2 5
HEC155 SNG-II
B
Tubulin
A
U
S
P
C
1
S
N
G
M
H
E
C
1
5
5
M
F
E
2
9
6
E
N
H
E
C
1
-
A
H
E
C
1
-
B
K
L
E
E
F
E
1
8
4
A
N
3
C
A
R
L
-
9
5
-
2
S
P
A
C
1
L
S
P
A
C
1
S
B
T
4
7
4
U
S
P
C
2
S
N
G
-
I
I
H
E
C
1
5
5
M
F
E
2
8
0
M
F
E
3
1
9
K
L
E
E
N
1
I
s
h
i
k
a
w
a
PTEN
Tubulin
Figure 2 (A) Dose-dependent activity of lapatinib on HER2, EGFR, AKT, and ERK phosphorylation in USPC1, USPC2, RL-95-2, HEC155, and SNG-II
cells. Both cell lines were treated with increasing doses of lapatinib (0.5–5mM) for 1h. Immunoprecipitation and western blotting to detect phosphorylated
HER2 or EGFR were performed as described in Materials and Methods. ERK and AKT phosphorylation levels were detected using phospho-specific ERK and
AKT antibodies as described in Materials and Methods. (B) Western blotting to detect PTEN expression was performed as described in Materials and
Methods.
Table 2 Correlations between IC50 values and the relative expression of
biomarkers in the 19 endometrial cancer cell lines
Name Symbol Spearman’s q P-value
EGFR EGFR  0.56 0.013
HER2 HER2  0.23 0.336
HER3 HER3  0.56 0.012
HER4 HER4 0.16 0.514
Epiregulin EREG  0.30 0.209
Amphiregulin AREG  0.56 0.012
Transforming growth factor-a TGFA  0.32 0.177
Heparin-binding EGF-like growth factor DTR  0.08 0.737
Betacellulin BTC 0.08 0.742
Neuregulin 1 NRG1  0.39 0.101
Neuregulin 2 NRG2 0.13 0.586
Estrogen receptor-a ESR1  0.20 0.403
Estrogen receptor-b ESR2  0.08 0.737
Progesterone receptor PGR  0.06 0.797
Androgen receptor AR 0.52 0.021
E-Cadherin CDH1  0.25 0.283
P-Cadherin CDH3  0.60 0.007
b-Catenin CTNNB1 0.16 0.495
Vimentin VIM 0.41 0.078
Cytokeratin 5 KRT5  0.01 0.988
Cytokeratin 6 KRT6 0.04 0.858
Cytokeratin 8 KRT8  0.47 0.043
Cytokeratin 18 KRT18  0.52 0.021
Cytokeratin 19 KRT19  0.69 0.001
EGFR¼epidermal growth factor receptor. Significant correlations are given in bold.
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ssuch as 8, 18, and 19 (eg, MFE296, HEC1B, AN3CA, EN1, EN, and
EFE184) (Figure 3B). These cell lines with post-EMT features
tended to be less sensitive towards lapatinib when compared with
those lines with an epithelial phenotype (mean IC50 5.84 vs 2.78,
P¼0.079). Conversely, we were able to demonstrate inverse
correlations between IC50 values and the relative expression of
CDH1 (r¼ 0.25, P¼0.283), CDH3 (r¼ 0.60, P¼0.007), and the
KRT8 (r¼ 0.47, P¼0.043), 18 (r¼ 0.52, P¼0.021), or 19
(r¼ 0.69, P¼0.001), suggesting that the epithelial phenotype
may be associated with lapatinib sensitivity.
Combinations of lapatinib and chemotherapeutics
In HER2-overexpressing breast cancer, the effect of chemotherapy
can be maximised when combined with trastuzumab or lapatinib
(Romond et al, 2005; Geyer et al, 2006). Thus, we next analysed the
combination of lapatinib and chemotherapeutic agents used for
the treatment of endometrial cancer in lapatinib-responsive
endometrial cancer cell lines. Multiple drug effect analysis was
performed using two HER2-overexpressing and two EGFR-
expressing established endometrial cancer cell lines to determine
the nature of the interaction between lapatinib and carboplatin,
paclitaxel, doxorubicin, or docetaxel (synergy, addition, or
antagonism). The lapatinib concentrations used for these experi-
ments ranged between 0.031 and 1.0mM for USPC1 and USPC2
cells, and 0.31 and 10.0mM for RL-95-2 and HEC155 cells and
were below the reported peak plasma concentrations achievable
in humans (Burris et al, 2004). The drug concentrations of
carboplatin, paclitaxel, doxorubicin, and docetaxel used for these
experiments have been published previously (Pegram et al, 2004).
Additive interactions were observed in all four endometrial cancer
cell lines for lapatinib plus carboplatin (mean CI values ranged
from 0.90 (P¼0.358) to 1.04 (P¼0.564)) (Figure 4). Synergistic
and additive interactions were observed for lapatinib plus
paclitaxel (0.69 (Po0.001) to 0.91 (P¼0.068)) and doxorubicin
(0.62 (Po0.001) to 0.89 (P¼0.341)) (Figure 4). Synergistic
interactions were observed for lapatinib plus docetaxel (0.68
(P¼0.001) to 0.78 (Po0.001)) in all four cell lines (Figure 4).
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Figure 3 (A) The red and green matrices represent the normalised expression patterns for each gene in Table 2 across the 19 endometrial cancer cell
lines. Brightest red indicates highest relative expression; brightest green indicates lowest relative expression. The reference cRNA pool consists of equal
amounts of cRNA from the 18 endometrial cancer cell lines. Cell lines are ordered from low IC50 values to high IC50 values. Genes are weighted according
to their correlation with the IC50 values. A negative correlation indicates that the marker is associated with sensitivity to lapatinib. (B) A cluster diagram of
the 19 endometrial cancer cell lines was developed using the markers VIM, CDH1, CDH3, and the KRT5, 6, 8, 18, and 19. Post-EMT cell lines showed high
expression of VIM, but low expression of CDH1, CDH3, and KRT8, 18, and 19 (eg, MFE296, HEC1B, AN3CA, EN1, EN, and EFE184).
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Figure 4 Mean CI values for chemotherapeutic drug–trastuzumab
combinations in four different human endometrial cancer cell lines. Error
bars indicate the 95% confidence interval of the mean value. Mean is
derived from three replicates spanning clinically relevant concentration
ranges sufficient to inhibit growth of control cells by 20–90%. Combination
index values were derived from parameters of the median effect plots, and
statistical tests were used to determine whether the CI values at multiple
effect levels (IC20–IC90) were statistically significantly different from CI
values equal to 1. Values that are statistically significantly less than 1 indicate
synergistic interactions. Values that are statistically significantly greater than
1 indicate antagonistic interactions. Values equal to (or not statistically
significantly different from) 1 indicate additive interactions.
Lapatinib in endometrial cancer
GE Konecny et al
1081
British Journal of Cancer (2008) 98(6), 1076–1084 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sDISCUSSION
Evidence for a role of HER2 and EGFR in the pathogenesis of
various cancers has led to the rational design and development of
agents that selectively target HER2 and EGFR. In unselected
patients with endometrial cancer, HER2 gene amplification/over-
expression represents a rare event. However, HER2 amplification/
overexpression is seen more commonly in well-defined subtypes of
endometrial cancer such as uterine serous papillary cancer, clear
cell cancer, or grade 3 endometrioid cancer (Morrison et al, 2006).
Trastuzumab (Herceptint) a humanised anti-HER2 antibody has
recently been approved for the adjuvant treatment of HER2-
overexpressing (3þ IHC) or FISH-positive primary breast cancers
based on a highly significant reduction in the risk of recurrence
of 52% in node-positive HER2-positive primary breast cancer
(Romond et al, 2005). Encouraged by these data, we intended to
evaluate the therapeutic potential of a dual kinase inhibitor
targeting both HER2 and EGFR for the treatment of endometrial
cancer and proposed to define markers that may help identify
patient subsets that would preferentially benefit from such a
target-based therapy.
To date, no studies have been reported that investigate the
activity of lapatinib in endometrial cancer cells. Here, we show
concentration-dependent anti-proliferative effects of lapatinib in
all endometrial cancer cell lines tested. The response, however,
varied significantly between individual cell lines with up to a 200-
fold difference in the IC50 values. As expected, significantly
lower IC50 values were associated with HER2 amplification/
overexpression. Surprisingly, increased EGFR expression was also
associated with improved in vitro response to lapatinib. This is
remarkable as it is in contrast to preclinical studies in breast
cancer, where no significant association between EGFR expression
and in vitro sensitivity to lapatinib was seen across a large panel of
breast cancer cell lines (Konecny et al, 2006). Epidermal growth
factor receptor may play a different role in endometrial cancer
compared with breast cancer. Importantly, the clinical benefit
observed with anti-EGFR TKIs across different disease entities has
been variable (eg, EGFR TKIs are largely inactive in colorectal
cancer); however, two of these drugs, gefitinib and erlotinib, have
demonstrated clinical activity in nonsmall cell lung cancer
(NSCLC) and responses have been observed in patients with
advanced pancreatic cancer and in head-and-neck cancer (Baselga,
2006). The current preclinical data suggest that EGFR inhibitors
may also be clinically active in well-defined subgroups of
endometrial cancer. Earlier clinical studies in other disease entities
show that potential markers of sensitivity to EGFR TKIs include
the presence of EGFR gene amplification, mutations of the EGFR
gene, and increased expression of EGFR ligands (Baselga and
Arteaga, 2005). The role of EGFR gene amplification or mutations
in endometrial cancer has not been studied yet. Our preclinical
findings, however, do suggest that increased expression of EGFR
ligands such as amphiregulin, TGF-a, epiregulin, or NRG1 may
also be associated with sensitivity to lapatinib in endometrial
cancer.
HER3 is the preferred heterodimerisation partner of HER2.
Ligand-induced stimulation of HER3 leads to the activation of
HER2 by transduction through heterodimerisation. Preclinical
data suggest that HER3 overexpression increases sensitivity to
TKIs such that sensitivity towards gefitinib was only seen in
NSCLC cell lines with increased expression of HER3 (Engelman
et al, 2005). Similarly, we also found a positive association between
HER3 expression levels and increased in vitro sensitivity to
lapatinib using the current panel of endometrial cancer cell lines.
Higher levels of HER3 expression may promote hetero-oligomer
formation with HER2 and EGFR and lead to increased activation of
the PI3K/AKT pathway. This pathway activation may in return
lead to increased sensitivity towards EGFR or HER2 inhibition by
lapatinib. Nevertheless, further research will be necessary to clearly
define the clinical value of HER3 as a predictive marker for small
molecule receptor TKIs in endometrial cancer.
An inverse association has been described between HER2
amplification/overexpression and the presence of receptors for
the steroid hormones oestrogen and progesterone in both clinical
correlative studies and experimental models for both breast and
endometrial cancer (Bigsby et al, 1992; Konecny et al, 2003;
Mariani et al, 2005). Preclinical data demonstrate that HER2
overexpression can lead to ligand-independent activation of the ER
and a reduction in the oestrogen-binding capacity of the cells (ie,
to decreased ER levels) and to a decrease in ER as well as PR
transcripts (Pietras et al, 1995). Moreover, recent laboratory
studies similarly confirm ligand-independent activation of the AR
through HER2 in prostate cancer cells (Sugita et al, 2004).
Consistent with these experimental findings, high EGFR and
HER2 expression was associated with low AR expression in the
present endometrial cancer cell line panel, thus suggesting that low
AR expression could be a useful surrogate marker for receptor
tyrosine kinase activation in endometrial cancer, possibly more
useful than ER or PR may be. However, further research will be
necessary to help define the predictive value of AR in endometrial
cancer, which in a recent study was found to be expressed in 39 out
of 44 (89%) patients with endometrioid endometrial cancer (Ito
et al, 2002).
Accumulating evidence points to a critical role of EMT-like
events during tumour progression. In this study, we found an
association between in vitro resistance to lapatinib and a post-EMT
cell line phenotype. Using the baseline expression arrays we were
able to discriminate ‘less responsive’ and ‘more responsive’ cell
lines using the differential expression of six genes: VIM, CDH1,
CDH3, and KRT8, 18, or 19. While other genes may be derived
from the analysis of large microarray data sets, the biologic
relevance of these genes makes them plausible predictive markers
worth further preclinical and clinical evaluation.
Antitumour activity of the HER2 antibody trastuzumab in
HER2-overexpressing breast cancers seems to be dependent upon
the presence of PTEN, a phosphatase that inhibits phosphatidy-
linositol 3-kinase-Akt signalling. Recently, it has been proposed
that trastuzumab can activate PTEN, which contributes to the
trastuzumab antitumour function (Nagata et al, 2004). Conse-
quently, PTEN deficiency, which occurs in up to 50% of breast
cancers, may predict for resistance to trastuzumab therapy (Nagata
et al, 2004). In contrast, however, recent preclinical studies with
lapatinib, demonstrate that the small molecule inhibitor exerts its
antitumour activity in a PTEN-independent manner (Xia et al,
2007). Our results confirm these observations in that lapatinib
activity was not associated with PTEN status in endometrial cancer
cells. The antitumour activity of lapatinib in a PTEN-independent
manner may be of particular importance for endometrial cancer as
PTEN deficiency is the most common genetic defect in endome-
trioid carcinoma and is seen in up to 83% of tumours that are
preceded by a histologically discrete premalignant phase (Hecht
and Mutter, 2006).
Patients most likely to be candidates for systemic therapies are
high-risk endometrial cancer subgroups with deep myometrial
invasion, positive lymph nodes, or type II endometrial cancers
with nonendometrioid histology (usually papillary serous or
clear cell). These are the patients most likely to also benefit
from adjuvant-targeted therapies. Our laboratory data provide a
clear biologic rational to test lapatinib as a single agent or in
combination with chemotherapy in HER2-overexpressing
and/or possibly EGFR-expressing endometrial cancer. Patients
most appropriate to screen for HER2 amplification are
patients with nonendometrioid histologies (type II). Further
evaluation of not only EGFR ligands and HER3 levels but also
AR levels and markers of EMT may help to define patients with
EGFR-expressing endometrial cancer most likely to respond to
lapatinib.
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